PaxVax appoints COO Farzan as president; Immunovaccine gets green light for RSV vaccine trial;

> PaxVax has appointed COO Nima Farzan as company president and COO. Release

> Takeda's vaccines president Rajeev Venkayya says his company is evaluating potential candidates in its pipeline that might have an impact on the Ebola virus. Interview

> Health Canada has cleared Immunovaccine to begin a Phase I trial of its RSV vaccine candidate. Release

> Two patients have been on Aduro Biotech's cancer vaccine combo regimen for more than two years and have snown no evidence of cumulative toxicity. Release

Half of girls ages 11-12, the age the CDC recommends, receive the HPV vaccine. Report

And Finally... A new study confirms long-held speculation that anti-vaccine sentiment can concentrate in communities, increasing the risk of outbreaks. Report

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.